NCT03982667

Research Title: Efficacy and Safety of Point- Of-care Procalcitonin Test to Reduce Antibiotic Exposure in VAP

Completed NA Last updated 15 July 2020

What this trial tests

NA trial testing PCT-guided group in Ventilator Associated Pneumonia in 100 participants. Completed in 1 July 2020.

Timeline

15 June 2019

Primary endpoint
1 July 2020

1 July 2020

Quick facts

Lead sponsor	Mohd Zulfakar Mazlan, MBBS
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	diagnostic
Enrollment	100
Start date	15 June 2019
Primary completion	1 July 2020
Estimated completion	1 July 2020
Sites	2 locations across Malaysia

Drugs / interventions tested

• PCT-guided group

Conditions studied

• Ventilator Associated Pneumonia — all drugs for Ventilator Associated Pneumonia →

Sponsor

Mohd Zulfakar Mazlan, MBBS

Who can join

18 and older, any sex, with Ventilator Associated Pneumonia. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Several studies have shown that PCT guidance can reduce the duration of antibiotic treatment for patients with bacterial infections in the ICU, without compromising the safety outcomes. However PCT is known to be more costly than standard biomarkers that commonly use in our ICU setup. This remain the main challenge for us whether by monitoring the PCT level, it can reduce both the duration of antibiotic simultaneously reduce the total cost of the treatment for the patients. A local study addressing efficacy, safety and cost analysis of PCT-guided antibiotic therapy in severe pneumonia patients is therefore warranted. Until the results from a local study become available, the utility of PCT to guide antibiotic duration in our patient population cannot be recommended.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

1. Efficacy and safety of the point-of-care procalcitonin test for determining the antibiotic treatment duration in patients with ventilator-associated pneumonia in the intensive care unit: a randomised controlled trial.
   Z Mazlan M, A H Ismail M, Ali S, Salmuna ZN, et al · · 2021 · cited 20× · PMID 34006044 · DOI 10.5114/ait.2021.104300